Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07627620 | Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 54 | Hunan Cancer HospitalOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT03671811 | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | active not recruiting | Phase 2 | 44 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | terminated | Phase 2 | 9 | University of OklahomaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07600515 | Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors(ANIHTA) | not yet recruiting | — | 100 | Instituto do Cancer do Estado de São PauloOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06024109 | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy(BARHYSTER) | recruiting | — | 132 | Aesculap AGINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 80 | MacroGenicsINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT07120945 | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)(Embrace Gyn) | active not recruiting | N/A | 70 | Medtronic - MITGINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03835819 | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | active not recruiting | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06042543 | Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs(EASTER) | recruiting | N/A | 3,200 | International Agency for Research on CancerOTHER | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06259448 | Feasibility of Optimizing Organized Cervical Cancer Screening by Urine Self-sampling(PAPPEES) | completed | N/A | 173 | University Hospital, BordeauxOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617818 | QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer | not yet recruiting | Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT04345003 | MR Elastography Parameters Impact on MR-HIFU Efficacy in Uterine Fibroids(ELASTUS) | completed | N/A | 40 | University Hospital, BordeauxOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05743517 | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) | recruiting | N/A | 192 | Northwestern UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06106165 | Improving Muslim Women's Uptake of Cancer Screening (IMCAN)(IMCAN) | completed | N/A | 169 | University of SunderlandOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612865 | People's Hospital of Xinjiang Uygur Autonomous Region | completed | N/A | 160 | People's Hospital of Xinjiang Uygur Autonomous RegionOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07613567 | A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 3 | 486 | Fujian Cancer HospitalOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06010160 | Game Changers for Cervical Cancer Prevention(GC-CCP) | completed | N/A | 936 | RANDOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06430320 | Ascertaining Longterm Outcomes of Fibroid Treatments(ALOFT) | active not recruiting | — | 700 | Henry Ford Health SystemOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605507 | Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer(HYPOCx-iRex) | active not recruiting | N/A | 40 | Siriraj HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07606677 | Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16/18+ Women | not yet recruiting | — | 1,465 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05359016 | Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique | active not recruiting | N/A | 9,014 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06102252 | Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma | completed | N/A | 60 | Sohag UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT07368205 | Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging(PRSTEC_multipr) | recruiting | — | 350 | University Hospital Hradec KraloveOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07594327 | Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer | enrolling by invitation | — | 21 | Tampere University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer(TREAT-EC) | not yet recruiting | Phase 2 | 30 | Rutgers, The State University of New JerseyOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT04008095 | Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer(COLTEP) | completed | — | 40 | University Hospital, BrestOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04219904 | PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04634617 | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors | active not recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07583329 | Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy(V-COSMOS) | not yet recruiting | — | 160 | Cukurova UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07597083 | Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors | recruiting | N/A | 60 | Beni-Suef UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05761951 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 4, 2026source: clinicaltrials